Compare Funko Inc (FNKO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

FNKO trades at $5.92, down 4.36% today, but maintains a bullish technical outlook with strong moving average signals. The company reported improved Q2 2026 results with 7% revenue growth to $207.7M and raised EBITDA guidance. Despite negative net margins, recent earnings beats and a low P/S ratio of 0.35 suggest undervaluation. Analyst sentiment is mixed with 43% buy ratings but no sell recommendations.

The outlook remains cautiously optimistic as Funko's turnaround strategy shows traction, though profitability challenges and negative cash flow from operations pose risks. The stock offers potential upside if management can sustain recent operational improvements and return to consistent profitability.

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.